Ekso exoskeleton for Spinal Cord Injury

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Spinal Cord InjuryEkso exoskeleton - Device
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a device called Ekso to see if it is safe and effective for people with spinal cord injuries or similar neurological weaknesses. The device helps the person stand, walk, and turn, and sit down. The trial will test if the person using Ekso can safely balance and walk without losing balance, and if they improve in weight shift and other activities.

Eligible Conditions
  • Spinal Cord Injury

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Testing Day 1 - 3 and follow up testing Week 6 and Week 12.

Week 12
Psychosocial Impact of Assistive Device Scale (PIADS)
Week 12
Change in 10 meter walk test from baseline in gait speed
Week 12
Change in 6 Minute Walk Test from baseline in distance, rate of perceived exhaustion (RPE), and oxygen uptake
Ratio of number of steps/walking time
Week 12
2 Minute Walk Test
Walk time to stand time ratio on a particular assistive device

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Ekso Safety and Efficacy
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Ekso exoskeleton · No Placebo Group · N/A

Ekso Safety and Efficacy
Device
Experimental Group · 1 Intervention: Ekso exoskeleton · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: testing day 1 - 3 and follow up testing week 6 and week 12.

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
173 Previous Clinical Trials
13,662 Total Patients Enrolled
United States Department of DefenseFED
779 Previous Clinical Trials
202,379 Total Patients Enrolled
Arun Jayaraman, PhDPrincipal InvestigatorRIC/Northwestern
5 Previous Clinical Trials
211 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: